ADVR Announces Stockholders Meeting Results
Advanced Viral Research Corp. (OTC Bulletin Board: ADVR) a bio-pharmaceutical company, today announced the results of its Special Stockholders Meeting held March 21, 2007. The stockholders approved four proposals at the meeting:
- Blank Check Preferred Stock. Approved an amendment to the Company’s Certificate of Incorporation to authorize the issuance of up to 50,000,000 shares of blank check preferred stock
- Increase in Number of Shares of Authorized Common Stock. Approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of the Company’s common stock from 1,000,000,000 shares to 2,000,000,000 shares
- Conforming Amendments to Certificate of Incorporation. Approved an amended and restated Certificate of Incorporation which amends the headings, terminology and numbering of the provisions within its current Certificate of Incorporation
- Stock Incentive Plan. Approved the adoption of ADVR’s 2007 Stock Incentive Plan
“I was impressed and delighted with the turnout at today’s meeting. The approval of all four proposals described in the proxy is an important reflection of our stockholder’s support for our plans going forward,” said Stephen Elliston, President and CEO of Advanced Viral Corp.
Advanced Viral Research Corp is a New York based biopharmaceutical company dedicated to improving patients' lives by researching, developing and bringing to market new and effective therapies for the systematic control of symptoms associated with cancer and other serious diseases. ADVR's lead product, AVR118 represents a new class of complex cytoprotective agents that target among other things, cachexia related disorders. AVR118 has also shown to have topical wound healing properties in animal models. Various degenerative conditions associated with body wasting (cachexia) such as cancer, HIV/AIDS and chronic inflammation are potential disease targets for AVR118 therapy. |
